<DOC>
	<DOCNO>NCT00886613</DOCNO>
	<brief_summary>A study two part ( Part A Part B ) evaluate responsiveness various biomarkers immunity Varicella-Zoster Virus ( VZV ) follow repeat immunization heat treat VZV vaccine V212 Zostavaxâ„¢ . The enrollment participant study conduct 2 part , Part A Part B . The first 42 eligible participant enrol Part A study . In Part A , reaction VZV skin test baseline evaluate 48 72 hour post administration VZV skin test reagent saline ( opposite arm ) , 2 examiner perform reading timepoint ; subsequent skin test reading Part A perform 48 hour post administration . After skin test reaction obtain baseline 42 subject Part A , interim analysis perform ( 1 ) ass frequency baseline negative skin test order confirm plan sample size ( N=120 ) adequate evaluation effect vaccination VZV Skin Test , ( 2 ) ass frequency baseline positive skin test 72 hour relative 48 hour ( post administration ) order determine preferred time evaluation skin test reaction . The interim analysis Part A confirm study sample size , additional 78 subject enrol Part B achieve plan sample size ( N=120 ) . The study procedure Part B study identical Part A follow exception : ( 1 ) baseline skin test reading perform , either 48 72 hour ( post administration ) accommodate schedule clinic visit , ( 2 ) one examiner need skin test reading baseline .</brief_summary>
	<brief_title>A Study Evaluate Immunity Varicella Zoster Virus After Immunization With V212 Vaccine Zostavax ( V212-003 )</brief_title>
	<detailed_description>All eligible participant , regardless treatment group , administer three injection varicella antigen ( VZV Skin Test reagent ) , baseline first vaccination , second time second vaccination , third time approximately 14 day second vaccination . Reactions skin test assess examiner participant great extent possible .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant prior history Varicella Female participant nonchildbearing potential Participant hypersensitivity reaction vaccine component Participant prior history Herpes Zoster Participant receive Varicella Zoster vaccine include Zostavax Participant history immunosuppression cause disease , corticosteroid , cancer therapy organ transplant Participant active cancer Participant receive receive live virus vaccine inactivate virus vaccine 4 week prior participate study ( exception influenza vaccine ) Participant bedridden homebound</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>